nach oben

World Journal of Urology

Erschienen in:

13.01.2022 | Original Article

Management of patients with a persistently elevated PSA after radical prostatectomy: a narrative review

verfasst von: I. Latorzeff, G. Ploussard, M. D. Faye, U. Schick, N. Benziane-Ouaritini, T. M. Niazi, F. Saad, P. Sargos

Erschienen in: World Journal of Urology | Ausgabe 4/2022

Einloggen, um Zugang zu erhalten

Abstract

Introduction

The management of the postoperative biological relapse of prostate cancer is most often based on salvage radiotherapy (SRT) with or without the addition of a variable duration of hormone therapy (HT). The indications for SRT +/- HT are established in the setting of a rising PSA level after a period where an undetectable PSA was achieved. However, in case of detectable PSA immediately after radical prostatectomy, the treatment options and prognosis are still unclear.

Materials and Methods

We conducted a narrative review based on an analysis of the literature focusing on articles targeting the population of patients with postoperative persistently detectable PSA level. Case reports, original articles, clinical trials, and published reviews were studied for this purpose.

Conclusion

This article will describe current management of patients with detectable PSA immediately after radical prostatectomy, notably the contribution of modern imaging and new treatment options involving the combination of RT and HT.

Ploussard G, Fossati N, Wiegel T, D’Amico A, Hofman MS, Gillessen S et al (2021) Management of persistently elevated prostate-specific antigen after radical prostatectomy: a systematic review of the literature. Eur Urol Oncol 4(2):150–169CrossRef

Ravery V (1999) The significance of recurrent PSA after radical prostatectomy: benign versus malignant sources. Semin Urol Oncol 17(3):127–129PubMed

Preisser F, Chun FKH, Pompe RS, Heinze A, Salomon G, Graefen M et al (2019) Persistent prostate-specific antigen after radical prostatectomy and its impact on oncologic outcomes. Eur Urol 76(1):106–114CrossRef

Bolla M, van Poppel H, Collette L, van Cangh P, Vekemans K, Pozzo LD et al (2005) Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 366:572–578CrossRef

Ohri N, Dicker AP, Trabulsi EJ, Showalter TN (2012) Can early implementation of salvage radiotherapy for prostate cancer improve the therapeutic ratio? A systematic review and regression meta-analysis with radiobiological modelling. Eur J Cancer 48:837–44CrossRef

Ploussard G, Staerman F, Pierrevelcin J, Saad R, Beauval JB, Roupret M et al (2013) Predictive factors of oncologic outcomes in patients who do not achieve undetectable prostate specific antigen after radical prostatectomy. Committee Cancerology of the Association of French Urology. J Urol. 190(5):1750–6CrossRef

Fossati N, Cozzarini C, Fiorino C, Gandaglia G, Montorsi F, Briganti A (2017) Salvage radiation therapy for increasing prostate-specific antigen after radical prostatectomy: who, when, and how? J Clin Oncol 35(4):469–470CrossRef

Inagaki T, Kohjimoto Y, Nishizawa S, Kuramoto T, Nanpo Y, Fujii R et al (2009) PSA at postoperative three months can predict biochemical recurrence in patients with pathological T3 prostate cancer following radical prostatectomy. Int J Urol 16(12):941–946CrossRef

Gandaglia G, Boorjian SA, Parker WP, Zaffuto E, Fossati N, Bandini M et al (2017) Impact of postoperative radiotherapy in men with persistently elevated prostate-specific antigen after radical prostatectomy for prostate cancer: a long-term survival analysis. Eur Urol 72(6):910–917CrossRef

10.

Stish BJ, Pisansky TM, Harmsen WS, Davis BJ, Tzou KS, Choo R et al (2016) Improved metastasis-free and survival outcomes with early salvage radiotherapy in men with detectable prostate-specific antigen after prostatectomy for prostate cancer. J Clin Oncol 34(32):3864–3871CrossRef

11.

Fossati N, Karnes RJ, Colicchia M, Boorjian SA, Bossi A, Seisen T et al (2018) Impact of early salvage radiation therapy in patients with persistently elevated or rising prostate-specific antigen after radical prostatectomy. Eur Urol 73(3):436–444CrossRef

12.

Ploussard G, Staerman F, Pierrevelcin J, Larue S, Villers A, Ouzzane A et al (2014) Clinical outcomes after salvage radiotherapy without androgen deprivation therapy in patients with persistently detectable PSA after radical prostatectomy: results from a national multicentre study. Committee of Cancerology (CCAFU) of the Association of French Urology (AFU). World J Urol. 32(5):1331–8CrossRef

13.

Bartkowiak D, Siegmann A, Böhmer D, Budach V, Wiegel T (2019) The impact of prostate-specific antigen persistence after radical prostatectomy on the efficacy of salvage radiotherapy in patients with primary N0 prostate cancer. BJU Int 124(5):785–791CrossRef

14.

Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D et al (2009) Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term follow-up of a randomized clinical trial. J Urol 181:956–962CrossRef

15.

Swanson GP, Hussey MA, Tangen CM, Chin J, Messing E, Canby-Hagino E et al (2007) Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794. J Clin Oncol 25(16):2225–2229CrossRef

16.

Wiegel T, Bartkowiak D, Bottke D, Bronner C, Steiner U, Siegmann A et al (2014) Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96–02/AUO AP 09/95 trial. Eur Urol 66(2):243–250CrossRef

17.

Dess RT, Sun Y, Jackson WC, Jairath NK, Kishan AU, Wallington DG et al (2020) Association of presalvage radiotherapy PSA levels after prostatectomy with outcomes of long-term antiandrogen therapy in men with prostate cancer. JAMA Oncol 6(5):735–743CrossRef

18.

Sood A, Keeley J, Palma-Zamora I, Arora S, Dalela D, Olson P et al (2020) Ten-year disease progression and mortality rates in men who experience biochemical recurrence versus persistence after radical prostatectomy and undergo salvage radiation therapy: a post-hoc analysis of RTOG 9601 trial data. Urol Oncol. 38(6):599.e1-599CrossRef

19.

Carrie C, Magné N, Burban-Provost P, Sargos P, Latorzeff I, Lagrange J-L et al (2019) Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial. Lancet Oncol 20:1740–1749CrossRef

20.

King CR (2016) The dose–response of salvage radiotherapy following radical prostatectomy: a systematic review and meta-analysis. Radiother Oncol 121(2):199–203CrossRef

21.

Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M et al (2021) EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: treatment of relapsing and metastatic prostate cancer. Eur Urol. 79(2):263–282CrossRef

22.

Alberts IL, Seide SE, Mingels C, Bohn KP, Shi K, Zacho HD et al (2021) Comparing the diagnostic performance of radiotracers in recurrent prostate cancer: a systematic review and network meta-analysis. Eur J Nucl Med Mol Imaging 48(9):2978–2989CrossRef

23.

Calais J, Czernin J, Fendler WP, Elashoff D, Nickols NG (2019) Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]. BMC Cancer 19:18CrossRef

24.

Jani AB, Schreibmann E, Goyal S, Halkar R, Hershatter B, Rossi PJ et al (2021) (18)F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial. Lancet 397(10288):1895–1904CrossRef

25.

Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C et al (2019) 18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. Lancet Oncol 20(9):1286–1294CrossRef

26.

Ghadjar P, Hayoz S, Bernhard J, Zwahlen DR, Hölscher T, Gut P et al (2021) Dose-intensified versus conventional-dose salvage radiotherapy for biochemically recurrent prostate cancer after prostatectomy: the SAKK 09/10 Randomized Phase 3 Trial. Eur Urol S0302–2838(21):01802–01809

27.

Pollack A, Karrison TG, Balogh AG, Low D, Bruner DW, Wefel JS et al (2018) Short term androgen deprivation therapy without or with pelvic lymph node treatment added to prostate bed only salvage radiotherapy: the NRG Oncology/RTOG 0534 SPPORT Trial. Int J Radiat Oncol Biol Phys 102:1605CrossRef

28.

Robin S, Jolicoeur M, Palumbo S, Zilli T, Crehange G, De Hertogh O et al (2021) Prostate bed delineation guidelines for postoperative radiation therapy: on behalf of the francophone group of urological radiation therapy. Int J Radiat Oncol Biol Phys 109(5):1243–1253CrossRef

29.

Vilotte F, Antoine M, Bobin M, Latorzeff I, Supiot S, Richaud P et al (2017) Post-prostatectomy image-guided radiotherapy: the invisible target concept. Front Oncol 9(7):34. https://doi.org/10.3389/fonc.2017.00034CrossRef

30.

Latorzeff I, Guerif S, Fraisse J, Meyer E, Supiot S, Lagneau E et al (2019) Late toxicity and quality of life from GETUG-AFU 22 Study: a multicenter randomized phase II trial comparing radiotherapy +/- 6 months of degarelix as a salvage treatment for patients with detectable PSA after radical prostatectomy. Int J Radiat Oncol. 105(1):S134CrossRef

31.

Feng FY, Huang HC, Spratt DE, Zhao SG, Sandler HM, Simko JP et al (2021) Validation of a 22-gene genomic classifier in patients with recurrent prostate cancer: an ancillary study of the NRG/RTOG 9601 randomized clinical trial. JAMA Oncol 7(4):544–552CrossRef

Titel: Management of patients with a persistently elevated PSA after radical prostatectomy: a narrative review
verfasst von: I. Latorzeff
G. Ploussard
M. D. Faye
U. Schick
N. Benziane-Ouaritini
T. M. Niazi
F. Saad
P. Sargos
Publikationsdatum: 13.01.2022
Verlag: Springer Berlin Heidelberg
Erschienen in: World Journal of Urology / Ausgabe 4/2022
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-021-03923-y

Neu im Fachgebiet Urologie

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Management of patients with a persistently elevated PSA after radical prostatectomy: a narrative review